Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 99 systematic review(s)/meta-analysis(es). ^[1-99]
• Effectiveness in Fatigue for Axial Spondyloarthritis (axSpA): Secukinumab demonstrated effectiveness in reducing fatigue across three out of four studies, with a dose-dependent effect observed for secukinumab specifically. Its effects were comparable to anti-tumor necrosis factor (TNF) and Janus kinase (JAK) inhibitors in axSpA fatigue management.
• Generalized Pustular Psoriasis (GPP) in Pediatric Patients: In a cohort of 46 pediatric patients with GPP, secukinumab achieved substantial efficacy, with 96% reaching complete lesion clearance (Generalized Pustular Psoriasis Area and Severity Index (GPPASI) 100 or Japan Dermatology Association (JDA) 0) and all patients attaining a GPPASI score of 90 or higher.
• Mental Disorders (MDs) in Psoriasis: Secukinumab was shown to effectively alleviate symptoms of mental disorders, with a particularly strong effect on anxiety (Hospital Anxiety and Depression Scale - Anxiety (HADS-A) index) among patients with psoriasis, standing out in its impact on MD-related outcomes compared to other therapies.
• Drug Survival and Persistence in Psoriasis: Secukinumab displayed high drug survival rates, with estimates exceeding 0.8 at one year, especially in biologic-naive patients, although it ranked lower in long-term persistence compared to other agents like guselkumab and risankizumab.
• General Safety in axSpA: Secukinumab demonstrated no significant safety concerns for patients with axial spondyloarthritis, with a generally favorable tolerability profile.
• Adverse Events in Pediatric GPP: Among children with generalized pustular psoriasis, 17% experienced adverse events related to secukinumab, though none were classified as severe.
• Risk of Major Adverse Cardiovascular Events (MACEs): Secukinumab did not show a significant increase in the risk of MACEs in patients with psoriasis or psoriatic arthritis, maintaining a safety profile consistent with other IL-17 inhibitors.
• Injection Site Reactions: Secukinumab had one of the lowest rates of injection site reactions (1.9%) among biologics, alongside nasopharyngitis and upper respiratory tract infections as the most common adverse events in nail psoriasis treatment.
• Axial Spondyloarthritis and Fatigue: Secukinumab demonstrated greater effectiveness in reducing fatigue among men and patients with non-radiographic axial spondyloarthritis, highlighting specific subgroup responses within this population.